© 2019 Opertech Bio, Inc.

 

DR. IRWIN SCHER

Chairman

 

 Dr. Scher is certified by the American Board of Rheumatology and American Board of Internal Medicine. He received his M.D. from Albert Einstein College of Medicine in New York and completed residencies at Presbyterian Hospital, University of Pittsburgh Medical Center, and Albert Einstein College of Medicine. Dr. Scher holds a B.S. in Chemistry from the State University of New York at Albany.​

Following his medical training he joined the Navy, eventually attaining a position as Captain USN Medical Corps at the Bethesda Naval Medical Complex. While there, Dr. Scher served as Professor of Medicine, Uniformed Services University, and Head, Immunology Branch, Naval Medical Research Institute. Following that, he spent 22 years in various positions at Merck, Astra/Merck, Astra Zeneca, and as Consultant to the Chief Executive Officer at Merck KGaA. From 2005-2011, Dr. Scher was the President and Chief Executive Officer of Biosynexus, a biotechnology company focused on treating and preventing Staphylococcal infections.

Dr. Scher has been on the board of Intarcia Therapeutics since 2007 and is Chairman and a Founder of Opertech Bio. He is currently actively involved as an angle investor in five startup biologically-focused companies.


 

  

 

KEVIN KLEINSCHMIDT

Director

  Kevin Kleinschmidt is a private investor and partner at Gabriel Investments, and is currently involved with over a dozen early stage ventures. Kevin is also a director at Careerminds, as well as a board or CEO advisor for several other businesses. Previously, he was co-founder and president, then CEO, of West Philadelphia-based Energy Plus, an energy marketing company that grew to over $350 million in annual revenue in 5 years and was acquired by NRG Energy in 2011. Prior to this, Kevin served as managing director of both partnership marketing and strategic planning and financing for Juniper Bank, a venture-backed start up, and then Barclays Bank (which purchased Juniper in 2005). At Juniper, Kevin led financing efforts which secured over $250 million in venture backing, and helped grow the partnership business to over $3 billion in annual transaction volume through strategic alliances with US Airways, Apple, and Barnes & Noble among many others.  

 

Kevin began his career in New York, in finance and investment banking at JP Morgan and then Morgan Stanley. Kevin serves as a trustee, board, or advisory board member at several local nonprofit arts and education organizations, including WXPN, Fringe Arts, The Mann Center, The Lantern Theater, KIPP, Philadelphia Classical School, and Liberti Center City. Kevin has an undergraduate degree from The College of William and Mary, and a MBA in finance and accounting from NYU.

  

 

Please reload

LATEST NEWS

SERVICES

We offer our customers a pioneering approach to measuring taste.

 

TASTE TESTERS

Are you interested in participating in one of our taste test studies?

 

TECHNOLOGY

MOG is an entirely new approach to taste testing, evaluation, and measurement.

 

MENU

SUBSCRIBE FOR NEWS

Receive the latest news and press releases exclusively from Opertech Bio.

CONNECT WITH US

  • YouTube - Black Circle
  • Google+ - Black Circle
  • LinkedIn - Black Circle